Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.50 |
| ▸ | CHUK | O15111 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 9/20 | 0.40 |
| ▸ | CDK1 | P06493 | 7/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.40 |
| ▸ | CDK7 | P50613 | 4/20 | 0.40 |
| ▸ | CDK9 | P50750 | 4/20 | 0.40 |
| ▸ | CCNH | P51946 | 4/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700100 | 0.93 | IKBKB (0.46) | IKBKBCHUKBRD4CDK2CDK1 | |
| SCHEMBL1700101 | 0.93 | IKBKB (0.46) | IKBKBCHUKBRD4CDK2CDK1 | |
| Trifluoroacetic Acid SCHEMBL1700504 | 0.90 | IKBKB (0.43) | IKBKBCHUKBRD4CDK2CDK1 | |
| SCHEMBL1700201 | 0.85 | P2RX4 (0.42) | BRD4CDK2CDK1CCNB1CCNT1 | |
| SCHEMBL30622023 | 0.82 | BRD4 (0.44) | IKBKBCHUKBRD4CDK2CDK1 | |
| SCHEMBL1700968 | 0.82 | BRD4 (0.44) | IKBKBCHUKBRD4CDK2CDK1 | |
| SCHEMBL1700611 | 0.82 | SCN9A (0.43) | IKBKBCHUKBRD4CDK2CDK1 | |
| SCHEMBL1700454 | 0.82 | BRD4 (0.44) | IKBKBCHUKBRD4CDK2CDK1 | |
| SCHEMBL1700455 | 0.82 | BRD4 (0.44) | IKBKBCHUKBRD4CDK2CDK1 | |
| SCHEMBL1700477 | 0.81 | BRD4 (0.43) | IKBKBCHUKBRD4CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4218731-A2 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220315555-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-11369599-B2 | Melt-extruded solid dispersions containing an apoptosis-inducing agent | ABBVIE INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220125796-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11369599-B2 | Melt-extruded solid dispersions containing an apoptosis-inducing agent | BCL2, BAX, BCL2L1 | IKBKB 450/4885CHUK 971/4885BRD4 2958/4885 |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | IKBKB 88/4885CHUK 112/4885BRD4 304/4885 |
| US-20220125796-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | IKBKB 724/4885CHUK 551/4885BRD4 2261/4885 |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | BCL2, BAX, BCL3 | IKBKB 88/4885CHUK 112/4885BRD4 304/4885 |
| US-20220315555-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | IKBKB 88/4885CHUK 112/4885BRD4 304/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | IKBKB 88/4885CHUK 112/4885BRD4 304/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | IKBKB 724/4885CHUK 551/4885BRD4 2261/4885 |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | IKBKB 88/4885CHUK 112/4885BRD4 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.